Related Experiment Video
Updated: May 20, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy
A Savonarola1, R Palmirotta, F Guadagni
1Department of Internal Medicine and Clinical Oncology, University of Bari Aldo Moro--Piazza Giulio Cesare 11, Bari, Italy. annalisa.savonarola@gmail.com
Abstract:
The goal of cancer pharmacogenomics is to obtain benefit from personalized approaches of cancer treatment and prevention. Recent advances in genomic research have shed light on the crucial role of genetic variants, mainly involving genes encoding drug-metabolizing enzymes, drug transporters and targets, in driving different treatment responses among individuals, in terms of therapeutic efficacy and safety. Although a considerable amount of new targeted agents have been designed based on a finely understanding of molecular alterations in cancer, a wide gap between pharmacogenomic knowledge and clinical application still persists. This review focuses on the relevance of mutational analyses in predicting individual response to antitumor therapy, in order to improve the translational impact of genetic information on clinical practice.
Insights
Cancer pharmacogenomics uses genetic variants to personalize cancer treatment and prevention for better efficacy and safety. This review highlights how analyzing mutations can bridge the gap between genetic knowledge and clinical practice.
Area of Science:
- Oncology
- Pharmacogenomics
- Genetics
Background:
- Personalized cancer treatment relies on understanding individual genetic variations.
- Genetic variants in drug-metabolizing enzymes, transporters, and targets influence treatment response.
- A gap exists between current pharmacogenomic knowledge and its clinical application.
Purpose of the Study:
- To review the significance of mutational analyses in predicting individual responses to cancer therapy.
- To enhance the translation of genetic information into clinical practice for improved cancer care.
Main Methods:
- Review of recent advances in genomic research related to cancer pharmacogenomics.
- Focus on mutational analyses for predicting treatment response.
- Analysis of the translational impact of genetic information.
Main Results:
- Genetic variants critically impact therapeutic efficacy and safety.
- Targeted cancer agents are increasingly designed based on molecular alterations.
- Despite advances, clinical application of pharmacogenomic knowledge remains limited.
Conclusions:
- Mutational analyses are relevant for predicting individual antitumor therapy response.
- Improving the translational impact of genetic information is crucial for clinical practice.
- Pharmacogenomics holds promise for personalized cancer treatment and prevention.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Principles of Pharmacogenetics: Types of Genetic Variants